產(chǎn)品名稱:5a-Dihydrotestosterone (DHT) RIA 產(chǎn) 地:Demeditec 產(chǎn)品貨號:DE5170 產(chǎn)品規(guī)格:96 Tests 產(chǎn)品說明: Special remarks: Intended use For in vitro determination of serum or plasma DHT levels. 5a-Dihydrotestosterone (DHT; 17ß-Hydroxy-5a-androstan-3-one), the most potent naturally-occurring androgen, is produced from testosterone through the action of cholestenone 5a-reductase. The concentrations of 5a-reductase are highest in certain peripheral tissues, including genital skin and hair follicles, and is localized intracellularly in apparent association with the nuclear membrane. DHT exerts its biological action by intracellular binding to the androgen receptor; this complex is then transferred to the nucleus where DNA-binding occurs with resultant effects on DNA transcription [2]. Most of the residual DHT undergoes intracellular metabolism to 3a-androstanediol and 3a-androstanediol glucuronide. Only a small proportion of DHT escapes into the peripheral circulation, where it is present primarily complexed to sex-hormone binding globulin. Testosterone causes virilization of the Wolffian ducts during fetal life, while DHT is responsible for the development of the male external genitalia and prostate, and is primarily responsible for the physical changes which occur during male sexual maturation. An autosomal-recessive genetic deficiency of 5a-reductase, sometimes called male pseudohermaphroditism or pseudovaginal perineoscrotal hypospadias, leads to inadequate differentiation of DHT-dependent peripheral tissues. Male infants with this disorder have ambiguous genitalia and are often raised as females, although significant virilization may occur later in life presumably due to the natural increase in testosterone levels. Measurement of DHT concentrations can be complicated by antibody cross-reactivity to testosterone. The DHT Double Antibody radioimmunoassay utilizes a sample oxidation / extraction procedure to remove most of the testosterone, coupled with a specific immunoassa. Principle of the method The procedure follows the basic principle of radioimmunoassay where there is competition between the radioactive and non-radioactive antigen for a fixed number of antibody binding sites. The amount of (I-125)-labeled analyte bound to the antibody is inversely proportional to the concentration of unlabeled analyte present. The separation of free and bound antigen is achieved by using a double antibody system. 上海玉博生物技術(shù)有限公司在為生命科學領(lǐng)域提供豐富的產(chǎn)品與信息資源方面處于國內(nèi)**地位,公司提供的產(chǎn)品涵蓋了二十多個國家近五十萬種產(chǎn)品,而且產(chǎn)品的數(shù)量與信息在不斷的增長和更新,公司提供的產(chǎn)品能夠使生命科學工作者加快對生物化學,分子生物學,細胞生物學以及蛋白質(zhì)組學研究的認知,以及分子診斷和臨床醫(yī)學領(lǐng)域的應(yīng)用。
滬公網(wǎng)安備 31011002002623號